NRx Says Its Ketamine Generic Cleared First-Cycle FDA Review With One Item Left — and Already Submitted. That Application Is the Anesthesia Label, Not Depression.

by Ellis Vance · August 18, 2026

Small-Cap Markets Correspondent, The SmallCap Signal

NRx Pharmaceuticals released second-quarter results Monday afternoon ahead of a 4:30 p.m. ET conference call, and the corporate-update section led with a regulatory item rather than a financial one. The Wilmington, Delaware-based company said it had "Completed first-cycle FDA review of the Company's ANDA for preservative-free ketamine with no drug-related major deficiencies," and that "The sole remaining item, a manufacturer's attestation on the vial, has been submitted to FDA," according to the release distributed by GlobeNewswire.

The release describes what that attestation is. "FDA requested that the Company provide a manufacturer's attestation that the vial is manufactured in the same manner as it is for 3 other currently approved drugs that ship more than 11.9 million units per year," it said. "This attestation has been provided to the FDA." So the outstanding item is not an action NRx still has to take; on the company's account it has been taken. What remains is the agency's decision on it, and the release does not say when that decision is expected beyond stating that the program "aims for 2026 approval and commercialization."

That is a genuinely narrow gate, and it is worth being precise about what lies on the other side of it — because Monday's release does not say. An Abbreviated New Drug Application is the pathway for a generic version of an already-approved drug, and the word "anesthesia" does not appear anywhere in Monday's document. NRx described the scope of that filing plainly in earlier disclosure. In a March 16, 2026 release posted to its investor relations site, the company said: "In addition to the pending New Drug Application for NRX-100 based on treatment of depression, NRx has a pending Abbreviated New Drug Application for the sale of preservative-free ketamine under its current label for use in anesthesia." The same release said that "FDA agreed to receive that application in September 2025 and assigned a Summer 2026 decision date."

The indication most investors associate with NRx — ketamine for severe depression with suicidal ideation — is not in that application. It sits in a separate New Drug Application for NRX-100. The March release described the FDA's guidance from a Type C meeting: "The minutes support FDA's willingness to review NRx's application for New Drug Approval of NRX-100 (preservative-free ketamine) based on Substantial Evidence of Effectiveness derived from existing adequate and well controlled trials," and "No additional clinical trials were requested." On the indication, the release said NRx "will seek a primary indication to treat depression in patients with severe depression who may have suicidal ideation, in place of the Company's original plan to treat only those with suicidal ideation" — a broadening of the proposed label, not a narrowing.

Monday's release does put a date on the NDA, and it is not this year. "NRx has continued to advance its New Drug Application for NRX-100 (Preservative-free ketamine) to treat depression," the release said. "During Q2, a Presidential Executive Order was signed and Congressional Budget Language was approved guiding the FDA to use Real World Evidence for approval of ketamine to treat depression. Evidence gathered from 65,000 Americans was presented at the American Society of Clinical Psychopharmacology meeting in Miami demonstrating that intravenous ketamine has greater or comparable efficacy to intranasal S-ketamine with more rapid onset in treating depression. With alignment on the drug packaging matter, the Company is now poised to finalize its NDA, aiming for 2027 approval."

That sentence also shows the two applications running together in NRx's own telling: the "drug packaging matter" is the vial attestation, which belongs to the ANDA, and it is offered as the thing that clears the way to finalize the NDA. Readers should also note that the company's descriptions of the NDA's status have not been consistent. The March 16 release called it a "pending New Drug Application." The May 18 first-quarter release said "The NRX-100 NDA, expected to be filed in Q2 2026, will be supported by clinical trial evidence in more than 1,000 patients and Real World Evidence." Monday's release, dated after the close of Q2, says the company is "poised to finalize" it. We are not resolving which rendering is right; the three do not agree, and Monday's document reports no FDA filing-acceptance decision and no review goal date.

So the two clocks run separately. The one that is close to the end is the generic filing, which prior disclosure places under the anesthesia label and which the company says aims at 2026 approval. The one that carries the depression indication is earlier in its life and is aimed at 2027. Both are real; they are not the same asset.

Chief executive and chairman Dr. Jonathan Javitt framed the quarter around commercialization. "The second quarter of 2026 was a major inflection point for NRx as we advance our mission to bring hope to the most vulnerable patients battling depression and suicidal ideation," he said in the release. "We have continued to drive towards our key objective of first commercial ketamine sales in 2026 with corresponding manufacturing operations and build-out of our first commercial team." He went further on the depression program than the release's own regulatory language does: "Our path to approval of NRX-100 has been advanced by support from the White House and Congress for the use of Real World Evidence that our drug has comparable or superior efficacy to that of current market leaders." That is a characterization of an application the same release describes as not yet finalized.

On the manufacturing side, the company said it had begun "Initiation of commercial scale manufacturing of preservative-free ketamine building to launch stock of 5 million doses to be ready for commercialization in 2026." It also said it had appointed Glenn Tyson as its first chief commercial officer and "retained a commercial launch team for preservative-free ketamine." The release does not disclose the cost of that inventory build or the terms under which it is being produced.

The financial section of Monday's release carries the heading "Financial Results for the Quarter Ended June 30, 2026" but reports no quarterly figures. Every number under it is a six-month number. NRx reported a net loss of $18.0 million for the six months ended June 30, 2026, against $23.1 million in the comparable 2025 period. "The change was primarily related to the impact of certain fair value accounting measurements and other non-recurring charges related to the conversion and restructuring of previously issued convertible notes incurred during the six months ended June 30, 2025," the release said. Net operating loss went the other way: $11.3 million for the six months, versus $7.6 million a year earlier. No income-statement table accompanies the release.

That presentation is a change from how the company has recently reported, and we checked the prior-year release rather than assuming it. The second-quarter 2025 earnings release gave three-month figures and no six-month figures at all: "For the three months ended June 30, 2025, the Company reported a net loss of $17.6 million versus a net loss of $7.9 million for the comparable quarter in 2024. The change was primarily attributable to fair value accounting measurements, which are non-cash." It reported a loss from operations of $3.7 million against $7.1 million, and approximately $2.9 million in cash at June 30, 2025. The May 2026 first-quarter release was also presented on a three-month basis. The direction of the change is therefore the reverse of the usual complaint: the prior-year comparative column in Monday's release contains six-month 2025 figures the company had not previously published in a quarterly release. A reader looking for the June 2026 quarter on its own will not find it in Monday's document.

The six-month 2025 comparatives are at least internally consistent with what NRx has published before. Subtracting the $17.6 million second-quarter 2025 net loss from the $23.1 million six-month figure leaves $5.5 million for the first quarter of 2025 — which is the figure the May 2026 release gives as the prior-year comparable quarter. That subtraction is ours, not the company's.

The June 2026 quarter can be approximated the same way, with the same caveat that this is our arithmetic rather than a reported figure and that the quarterly detail belongs in the Form 10-Q. NRx reported a net loss of $1.4 million for the three months ended March 31, 2026. Subtracting that from the six-month $18.0 million leaves roughly $16.6 million attributable to the second quarter. The Form 10-Q for the period was not available at the time of writing, and the release contains no quarterly income statement to check that against.

Cash is the line that improved most. NRx reported approximately $26.7 million in cash and cash equivalents at June 30, against $7.8 million at December 31, 2025 — and against $6.7 million at March 31, 2026, per the first-quarter release. The company's June public offering closed inside the quarter; Monday's release does not itemize the sources of the cash increase.

That offering is described in three documents, and the three are not measuring the same thing. The June 3 pricing release put the deal at 5,714,286 shares at $3.50 apiece, "approximately $20.0 million" in gross proceeds, "or $23.0 million if the underwriter exercises its option to purchase additional shares of Common Stock in full," with a 30-day option on up to 857,142 additional shares; both figures are stated before underwriting discounts and commissions, and no net-proceeds figure is given. BTIG was lead bookrunning manager and Lucid Capital Markets joint bookrunning manager. The June 4 closing release then reported the actual outcome: "The gross proceeds of the Offering were approximately $22.3 million before deducting underwriting discounts and commissions in the Offering and other estimated expenses payable by the Company, including exercise of the underwriters' option to purchase additional shares of common stock." A maximum-if-exercised figure and a gross-at-close figure are different quantities, and $23.0 million against $22.3 million is not a contradiction between them.

What does not sit easily is the characterization. Monday's release says the offering closed "for gross proceeds of $22.3 million, including full exercise of the underwriters' option." The June 4 closing release said only "including exercise," without the word full, and did not disclose how many option shares were purchased or the total share count. On the pricing release's own arithmetic, full exercise at $3.50 would have produced $23.0 million gross, not $22.3 million. We are not picking between the two characterizations and not adjusting the figure; the share count that settles it should appear in the Form 10-Q.

The funding-adequacy sentence in Monday's release is worth reading in full rather than in summary: "Management believes current cash resources, anticipated growth in clinic revenue, and opportunistic utilization of the Company's active at-the-market offering facility will be sufficient to support operations for at least one year." Two of the three legs of that statement are not cash in the bank. One is clinic revenue that the company expects to grow, and the release does not disclose what that revenue currently is. The other is an at-the-market equity facility, which by construction funds operations by issuing stock into the market — dilution is the mechanism, not a side effect. It is also a longer horizon than the company claimed a quarter earlier: the May release said the equivalent resources would "be sufficient to support operations through 2026." Holders sizing the runway should weigh the sentence with its qualifiers attached.

The clinic revenue in question comes from HOPE Therapeutics, the interventional psychiatry subsidiary NRx has been assembling. Monday's release said HOPE "expanded its clinical footprint with new sites in Sarasota and Boca Raton, Florida, and became the first commercial site in the US to treat patients using Zeta Surgical's FDA-cleared TMS navigation system." The May release described "First revenue generated from five interventional psychiatry clinics treating severe depression and PTSD," again without a dollar figure.

A second item in Monday's release deserves a side-by-side read against the underlying filing. NRx wrote that it was "Selected by the Defense Advanced Research Projects Agency (DARPA) as prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of NRX-101 with robotic TMS," with "Anticipated non-dilutive funding exceeds $11.5 million, subject to completion of contracting." The Form 8-K NRx filed on July 22, 2026 under Item 8.01 described the same event more conservatively: the proposal, "entitled Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) had been selected by DARPA for negotiation of a potential award." The filing closed with: "The selection of the Company's proposal for contract negotiation does not constitute a notice of award, a commitment by DARPA to make an award or an authorization for the Company to incur costs. Any potential award remains subject to the successful negotiation of definitive terms between DARPA/DSO and NRXD." The 8-K discloses no dollar amount anywhere. The counterparty on the NRx side is NRx Defense Systems, a Florida subsidiary.

The 8-K is not only more cautious; it is also more specific about the trial itself, and some of that detail is favourable. It states that the trial has been approved by the FDA as a Phase 2/3 study, that it is posted on clinicaltrials.gov under identifier NCT07227103, that planned sites include Harvard McLean, HOPE Therapeutics clinics and Walter Reed National Military Medical Center, and that NRX-101 has previously received FDA Breakthrough Therapy Designation.

The release also covers the GeNeuro assets NRx acquired, a portfolio of clinical-stage monoclonal antibodies spanning ALS (GNK-301), schizophrenia (Temelimab), multiple sclerosis and Type 1 diabetes. The release says GNK-301 "was co-invented at the US National Institute for Neurologic Diseases and Stroke" and that GeNeuro "is partnered with the US National Institutes of Health," and that "GNK-301's first-in-human trial is targeted for July 2027" — roughly eleven months out, and beyond the horizon of the one-year funding statement discussed above.

Several things a reader would want are not in any document we could reach. NRx's Form 10-Q for the June quarter was not available on EDGAR at the time of writing, so shares outstanding after the June offering, the total share count including option shares, the standalone second-quarter income statement, and any going-concern discussion by the auditors or management could not be confirmed. Monday's release states none of them: it contains no share count, no going-concern language, and no dollar figure for clinic revenue. For a company whose news is an approval timeline funded partly by an at-the-market equity facility, the size of the share base is a material unknown, and we are flagging it as unknown rather than estimating it.

The risks here are the ordinary ones for a company at this stage, stated plainly. Near-term revenue depends heavily on a single product whose first approval, if it comes, would be for a generic competing on price rather than on a protected indication. The depression indication depends on an NDA that Monday's release describes as not yet finalized, with approval aimed at 2027 and no disclosed acceptance or review timeline. The federal funding is not yet a contract. And the company's own sufficiency statement relies in part on selling stock through an ATM facility.

What to watch next: an FDA action on the ANDA — NRx's own documents render the expected timing differently, with the March release citing an "assigned" Summer 2026 decision date, the May release listing both "Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026" and a note that "FDA is endeavoring to complete the product review by Summer 2026," and Monday's release saying only that the program aims for 2026 approval, so the honest summary is sometime this year; the Form 10-Q, which should carry the standalone June-quarter income statement, the share count behind the June offering and any going-concern discussion; the filing and acceptance of the NRX-100 NDA; and whether the DARPA negotiation converts into an actual award with a stated dollar value.